PE20011177A1 - 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE - Google Patents

5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE

Info

Publication number
PE20011177A1
PE20011177A1 PE2001000216A PE2001000216A PE20011177A1 PE 20011177 A1 PE20011177 A1 PE 20011177A1 PE 2001000216 A PE2001000216 A PE 2001000216A PE 2001000216 A PE2001000216 A PE 2001000216A PE 20011177 A1 PE20011177 A1 PE 20011177A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrimidines
methyl
alkylpyride
cycline
Prior art date
Application number
PE2001000216A
Other languages
Spanish (es)
Inventor
Richard John Booth
Scott Norman Vanderwel
Peter Laurence Toogood
Ellen Myra Dobrusin
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20011177A1 publication Critical patent/PE20011177A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A DERIVADOS DE 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS DE FORMULA I DONDE R2 ES H, ALQUILO, CARBOCICLICO C3-C7; R3 ES H, ALQUILO, ALCOXI, HALOGENO, TRIFLUOROMETILO, ALQUINILO, ALQUENILO, ENTRE OTROS; Y ES N, CR7; R9 ES ALQUILO, HALOALQUILO, ARILO; X Y Z SON H, HALOGENO, ALQUILO, ALCOXI, TRIFLUOROMETILO, HIDROXI, NITRILO, NR4R5, ENTRE OTROS; R4 Y R5 SON H, ALQUILO, ALQUENILO, ALQUINILO, (CH2)nAr, ARILALQUILO, ARILO, HETEROARILO, HETEROARILALQUILO, ENTRE OTROS; R7 ES NR4R5, N(O)R4R5, OH, OR4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 8-CICLOPENTIL-5-METIL-2-(4-PIPERAZIN-1-IL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA,8-(1-METILETIL)-5-METIL-2-(4-PIPERAZIN-1-IL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA,8-CICLOPENTIL-5-METIL-2-(4-FLUORO-3-METIL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA, ENTRE OTROS. LOS COMPUESTOS DE 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORES DE TIROSINA CINASAS DEPENDIENTES DE CICLINA (Cdk) Y SON UTILES PARA EL TRATAMIENTO DE INFLAMACION, ENFERMEDADES PROLIFERATIVAS, CANCER, RESTENOSIS, ENFERMEDADES NEURODEGENERATIVASREFERS TO DERIVATIVES OF 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES OF FORMULA I WHERE R2 IS H, ALKYL, CARBOCYCLIC C3-C7; R3 IS H, ALKYL, ALCOXY, HALOGEN, TRIFLUOROMETHYL, ALKINYL, ALKENYL, AMONG OTHERS; Y IS N, CR7; R9 IS ALKYL, HALOALKYL, ARYL; X AND Z ARE H, HALOGEN, ALKYL, ALCOXY, TRIFLUOROMETHYL, HYDROXY, NITRILE, NR4R5, AMONG OTHERS; R4 AND R5 ARE H, ALKYL, ALKENYL, ALKINYL, (CH2) nAr, ARYLALKYL, ARYL, HETEROARYL, HETEROARYALKYL, AMONG OTHERS; R7 IS NR4R5, N (O) R4R5, OH, OR4, AMONG OTHERS. PREFERRED COMPOUNDS ARE 8-CYCLOPENTIL-5-METHYL-2- (4-PIPERAZIN-1-IL-PHENYLAMINE) -8H-PYRIDO [2,3] PYRIMIDIN-7-ONA, 8- (1-METHYLETHYL) -5-METHYL -2- (4-PIPERAZIN-1-IL-PHENYLAMINE) -8H-PYRIDO [2,3] PYRIMIDIN-7-ONA, 8-CYCLOPENTIL-5-METHYL-2- (4-FLUORO-3-METHYL-PHENYLAMINE) -8H-PIRIDO [2,3] PYRIMIDIN-7-ONA, AMONG OTHERS. THE COMPOUNDS OF 5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLINE-DEPENDENT TYROSINE KINASES (Cdk) AND ARE USEFUL FOR THE TREATMENT OF INFLAMMATION, PROLIFERATIVE DISEASES, CANCER, RESTENADESIS, ILLNESS

PE2001000216A 2000-03-06 2001-03-05 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE PE20011177A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
PE20011177A1 true PE20011177A1 (en) 2001-11-23

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000216A PE20011177A1 (en) 2000-03-06 2001-03-05 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1333833B1 (en) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases
WO2002064594A2 (en) * 2001-02-12 2002-08-22 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
BR0309053A (en) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compounds
CA2494061C (en) 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
ES2281843T3 (en) 2003-11-13 2007-10-01 F. Hoffmann-La Roche Ag PIRIDO-7-PIRIMIDIN-7-WAVES REPLACED WITH HYDROXIALQUIL.
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
JP2008510770A (en) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel pteridinone as a PLK inhibitor
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
CA2594860A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
JP2008535822A (en) 2005-03-25 2008-09-04 グラクソ グループ リミテッド New compounds
CN101495475A (en) 2005-03-25 2009-07-29 葛兰素集团有限公司 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
JP4718637B2 (en) 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors
AU2007311480A1 (en) * 2006-10-16 2008-04-24 Forma Therapeutics, Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
UA101611C2 (en) * 2007-04-03 2013-04-25 Аррей Байофарма Инк. Compounds of imidazo[1,2-a]pyridine as receptor tyrosine kinase inhibitors
RU2010101052A (en) * 2007-06-15 2011-07-20 Банью Фармасьютикал Ко., Лтд (Jp) Bicycloaniline derivatives
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
MX2010006457A (en) 2007-12-19 2010-07-05 Amgen Inc Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors.
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
AU2009233951B2 (en) * 2008-04-07 2014-02-27 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8101622B2 (en) 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CA2776770A1 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
KR101754664B1 (en) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
KR101434841B1 (en) * 2010-08-05 2014-08-29 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CA2830516C (en) 2011-03-23 2017-01-24 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
JP5974084B2 (en) * 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド Tyrosine kinase inhibitor
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
RU2619944C2 (en) * 2013-02-21 2017-05-22 Пфайзер Инк. Solid forms of selective cdk4/6 inhibitor
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
JP6631616B2 (en) * 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 2-Amino-pyrido [2,3-d] pyrimidin-7 (8H) -one derivatives as CDK inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
EP3497103B1 (en) 2016-08-15 2021-05-05 Pfizer Inc. Pyridopyrimdinone cdk2/4/6 inhibitors
EP3589634A4 (en) * 2017-03-03 2020-08-12 Auckland Uniservices Limited Fgfr kinase inhibitors and pharmaceutical uses
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
US20220024916A1 (en) * 2018-12-07 2022-01-27 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic comipound as cdk-hdac dual pathway inhibitor
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
WO2022188755A1 (en) * 2021-03-08 2022-09-15 暨南大学 Pyridopyrimidine-based compound and application thereof
CN117720531A (en) * 2022-09-16 2024-03-19 华东师范大学 Pyridopyrimidine derivatives as RSK inhibitors and use thereof
WO2024099403A1 (en) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
BR9911590A (en) * 1998-05-26 2001-02-13 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cell proliferation

Also Published As

Publication number Publication date
EA200200802A1 (en) 2003-02-27
AU2001233028A1 (en) 2001-10-03
KR20020075805A (en) 2002-10-05
BG107161A (en) 2003-06-30
IS6524A (en) 2002-08-23
HN2001000040A (en) 2001-09-06
HUP0300136A2 (en) 2003-05-28
CR6736A (en) 2004-03-10
IL151480A0 (en) 2003-04-10
GT200100037A (en) 2002-03-04
MXPA02008535A (en) 2002-12-13
TNSN01036A1 (en) 2005-11-10
MA26881A1 (en) 2004-12-20
CN1422268A (en) 2003-06-04
NO20024235D0 (en) 2002-09-05
PA8513201A1 (en) 2003-06-30
YU66502A (en) 2005-09-19
SV2001000338A (en) 2001-11-30
EP1268476A1 (en) 2003-01-02
JP2003528101A (en) 2003-09-24
AP2002002643A0 (en) 2002-12-31
NO20024235L (en) 2002-11-05
EE200200506A (en) 2004-02-16
CA2401368A1 (en) 2001-09-27
BR0109056A (en) 2003-06-03
CZ20022929A3 (en) 2003-02-12
HRP20020798A2 (en) 2004-02-29
DZ3308A1 (en) 2001-09-27
NZ520962A (en) 2003-09-26
WO2001070741A1 (en) 2001-09-27
OA12227A (en) 2004-03-18
AR034119A1 (en) 2004-02-04
CO5280200A1 (en) 2003-05-30
SK12472002A3 (en) 2003-04-01
ZA200207110B (en) 2003-12-04
PL358271A1 (en) 2004-08-09

Similar Documents

Publication Publication Date Title
PE20011177A1 (en) 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE
EA200500721A1 (en) Pyrimidines inhibiting CHK, PDK and ACT, THEIR RECEIVING AND USING AS MEDICINES
PE20021096A1 (en) DERIVATIVES OF 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PIRROLO [2,3-D] PYRIMIDINE AS INHIBITORS OF IGF-IR TYROSINE-KINASE
PE20021010A1 (en) SPIROCYCLIC DERIVATIVES AS PHOSPHODIESTERASE-7 INHIBITORS
UY27714A1 (en) 2 - HETEROARIL - CDK INHIBITING PYRIMIDINES, ITS PREPARATION AND ITS USE AS MEDICATIONS.
ECSP034831A (en) SUBSTITUTED DERIVATIVES OF 2-PYRIDINE CYCLHEXAN-1,4-DIAMINE
MXPA02011426A (en) bgr; CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE.
PE20020305A1 (en) 2- (4-PYRIDYL) AMINO-6-DIALCOXYPHENYL-PYRIDO [2,3-d] PYRIMIDIN-7-ONAS AS INHIBITORS OF TYROSINE KINASE
ECSP024399A (en) BENZOTIAZOL DERIVATIVES
ES2195785B1 (en) NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
PA8609201A1 (en) REPLACED PYRIDINONES
UY27604A1 (en) CHEMICAL COMPOUNDS.
PE20060504A1 (en) PYRIMIDINE DERIVATIVES IN THE TREATMENT OF CANCER
BR0206633A (en) 1-Aryl- or 1-Arylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
CU23148A3 (en) AZAPOLICICLIC COMPOUNDS CONDENSED WITH ARILO
SV1999000009A (en) DERIVATIVES OF 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL REF. PG3388 / SV
PA8432901A1 (en) PIRIDILPIRROL COMPOUNDS
PE20030739A1 (en) ADENOSINE A2A RECEPTOR ANTAGONISTS
PE20020594A1 (en) ARIL-SUBSTITUTED INDIRUBIN DERIVATIVES, THEIR PREPARATION AND USE
BR0215151A (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
CO5170529A1 (en) DERIVATIVES OF 5- (REPLACED PHENYL) -2-PIPERAZINIL-PIRIMIDIN- (3,5- BISTRIFLUORO-METIL-BENCIL) -METIL-AMIDA
ECSP055693A (en) PROCESS FOR SYNTHESIS OF USEFUL INTERMEDIARIES FOR SYNTHESIS OF TUBULIN INHIBITORS
ATE346067T1 (en) CARBOLINE DERIVATIVES
ECSP045156A (en) INDOLILALQUILAMINE DERIVATIVES AS LIGANDOS 5-HIDROXITRIPTAMINA-6
ECSP034917A (en) NEW DERIVATIVES OF SULFONIC ACID

Legal Events

Date Code Title Description
FC Refusal